Fig. 2

JAK2 inhibitor prevents LPS+MV-induced lung injury in mice. Mice were selected from those in non-ventilated control group or those subjected to 0.3 mg/kg LPS and MV with a tidal volume of 20 ml/kg for 6 h (n = 6 per group). AZD1480 40 mg/kg was administered intraperitoneally 30 min before PBS or LPS aspiration. a Representative histological images of the lungs from mice treated as indicated. Scale bar = 100 μm. b Lung injury score in different groups. c Lung permeability was assessed by measuring total BALF protein level. d ELISA assay of TNF-α level in BALF. e ELISA assay of IL-1β level in BALF. f ELISA assay of IL-6 level in BALF. g ELISA assay of MPO level in BALF. h ELISA assay of HMGB1 level in BALF. i Representative blots showing the levels of phosphorylation of JAK2 and STAT1 in lung lysate from mice treated as indicated. j Desitometry analysis of the phosphorylation of JAK2 level in lung lysate from mice treated as indicated. k Densitometry analysis of phosphorylation of STAT1 level in different groups. l Representative blots showing the levels of LC3- I, LC3-II, cleaved caspase 3, and total caspase 3 in lung lysate from mice treated as indicated. m Densitometry analysis of LC3-II/LC3-I level in different groups. n Densitometry analysis of cleaved caspase 3/caspase 3 in different grops. Data represented the mean ± SEM. *p < 0.05, **p < 0.001, and ***p < 0.001, compared with the control. ^##p < 0.01 and ^###p < 0.001, compared with the LPS. ^&p < 0.01, ^&&p < 0.01, and ^&&&p < 0.001, compared with the LPS+MV